We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Bio-Thera

News List

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506 americanpharmaceuticalreview
June 10, 2021
Bio-Thera Solutions Ltd., a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase III clinical study for BAT2506, a proposed biosimilar of Simponi® (golimumab).
Biogen and Bio-Thera enter licencing agreement for arthritis biosimilar pharmaceutical-technology
April 12, 2021
Biogen and Bio-Thera Solutions have entered an agreement to develop, manufacture and commercialise the anti-interleukin-6 (IL-6) receptor monoclonal antibody BAT1806.
Breaking News! China’s Humira Biosimilar Produced by Bio-Thera to be Marketed Soon PharmaSources/Caicai
November 05, 2019
The marketing application of Bio-Thera’s adalimumab (acceptance No.: CXSS1800018) has recently been under the “under approval” status, which is expected to be approved for marketing soon for treating ankylosing spondylitis (AS).
Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT4306F, an ADCC-Enhanced CD20 Monoclonal Antibody americanpharmaceuticalreview
December 10, 2018
Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that patient dosing has begun in a Phase I clinical study of BAT4306F in....